Showing 5 posts of 5 posts found.


Gilead’s PrEP drug Descovy should be approved for men and transgender women but not cis-gender women, FDA advisory panel says

August 8, 2019
Research and Development AIDS, Gilead, HIV, PrEP, descovy, pharma

Independent experts on a panel advising the FDA have voted in favour of Gilead’s new PrEP drug Descovy in men …


Gilead will give 11 years’ worth of PrEP drugs to those at risk of HIV after ‘discussions’ with Trump

May 10, 2019
Medical Communications Gilead, HIV, PrEP, Trump, Truvada, descovy

Gilead Sciences has agreed to donate 11 years’ worth PrEP drugs for up to 200,000 individuals each year, following “discussions …


FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

February 8, 2018
Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.


EU grants approval for Gilead’s HIV treatment Descovy

April 26, 2016
Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf

Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …


FDA approves Gilead’s latest HIV treatment

April 5, 2016
Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …

Latest content